Your browser is no longer supported. Please, upgrade your browser.
We’ve redesigned our maps and bubbles! Read more about the new features here. ×
Actavis plc
IndexS&P 500 P/E- EPS (ttm)-4.18 Insider Own0.10% Shs Outstand266.25M Perf Week0.12%
Market Cap77.15B Forward P/E13.86 EPS next Y20.92 Insider Trans0.00% Shs Float265.08M Perf Month3.42%
Income-1046.00M PEG- EPS next Q4.05 Inst Own95.60% Short Float7.93% Perf Quarter8.58%
Sales11.78B P/S6.55 EPS this Y-793.40% Inst Trans8.05% Short Ratio7.66 Perf Half Y27.25%
Book/sh110.26 P/B2.63 EPS next Y19.82% ROA-3.10% Target Price322.33 Perf Year27.51%
Cash/sh1.28 P/C226.66 EPS next 5Y21.00% ROE-6.60% 52W Range184.71 - 296.77 Perf YTD12.58%
Dividend- P/FCF45.75 EPS past 5Y-35.20% ROI-3.00% 52W High-2.36% Beta0.32
Dividend %- Quick Ratio0.80 Sales past 5Y27.90% Gross Margin49.60% 52W Low56.88% ATR6.61
Employees19200 Current Ratio1.40 Sales Q/Q83.00% Oper. Margin-0.20% RSI (14)61.69 Volatility1.89% 2.47%
OptionableYes Debt/Eq0.53 EPS Q/Q-906.10% Profit Margin-8.10% Rel Volume1.17 Prev Close290.40
ShortableYes LT Debt/Eq0.52 EarningsFeb 18 BMO Payout- Avg Volume2.75M Price289.78
Recom1.60 SMA203.65% SMA506.95% SMA20020.90% Volume3,206,511 Change-0.21%
Feb-20-15Reiterated Argus Buy $310 → $340
Feb-19-15Reiterated RBC Capital Mkts Top Pick $325 → $330
Feb-19-15Reiterated Canaccord Genuity Buy $300 → $352
Jan-21-15Reiterated Deutsche Bank Buy $280 → $330
Jan-13-15Reiterated CRT Capital Buy $270 → $288
Nov-21-14Reiterated Argus Buy $285 → $310
Nov-20-14Reiterated RBC Capital Mkts Top Pick $291 → $323
Nov-18-14Reiterated UBS Buy $278 → $333
Nov-06-14Reiterated RBC Capital Mkts Top Pick $286 → $291
Sep-22-14Downgrade Barclays Overweight → Equal Weight $250 → $250
Aug-06-14Reiterated UBS Buy $237 → $254
Jul-02-14Reiterated CRT Capital Buy $245 → $275
Jun-27-14Initiated Canaccord Genuity Buy $275
May-12-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
May-01-14Reiterated CRT Capital Buy $230 → $245
Apr-28-14Reiterated National Alliance Securities Buy $246 → $259
Apr-17-14Initiated National Alliance Securities Buy $246
Feb-21-14Reiterated RBC Capital Mkts Outperform $240 → $249
Feb-19-14Reiterated UBS Buy $202 → $237
Feb-19-14Reiterated CRT Capital Buy $210 → $230
Feb-26-15 11:50AM  Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog Zacks
Feb-25-15 06:02PM  FDA approves new antibiotic combo from Actavis AP
05:21PM  Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM) PR Newswire
02:31PM  Biotech Pharmacyclics Spikes On Buyout Rumors at Investor's Business Daily
01:04PM  ACTAVIS PLC Financials EDGAR Online Financials
11:00AM  Eight Undervalued Key Antibiotics Players at
09:56AM  13F Filings Takeaway: Own A Dirty Dozen at Forbes
08:21AM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:00AM  Actavis Announces Pricing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan PR Newswire
Feb-24-15 05:22PM  Stock Chart Symmetry Shows A Beautiful Base Is Less Risky Investor's Business Daily
03:58PM  Lannett Joins Big-Game Hunt For Drugmaker Acquisitions at Investor's Business Daily
03:39PM  Allergan, Inc. (AGN), HCA Holdings Inc (HCA), Gilead Sciences, Inc. (GILD) Among Healthcare Stocks That Billionaires Love at Insider Monkey
Feb-23-15 07:53PM  Valeant Pharma (VRX) Soars on Salix Buy: 3 Keys for Investors - Stocks in the News Zacks
06:51PM  With Inversion Ban, Foreign Suitors Can Outbid Homegrown Investor's Business Daily
06:22PM  Five Top-Rated Medical Stocks To Keep Monitoring at Investor's Business Daily
04:49PM  Monday's Market Recap Yahoo Finance Contributors
03:09PM  Jim Cramer Says Investors Should Buy Valeant Pharmaceuticals (VRX) After It Acquired Salix at TheStreet
12:41PM  Pharma M&A: Bristol-Myers, Valeant Make Deals at Investor's Business Daily
Feb-22-15 07:12PM  Valeant Pharmaceuticals Will Buy Salix For $14.5 Billion at Investor's Business Daily
05:06PM  Valeant agrees to buy Salix for $14.5bn at Financial Times
Feb-20-15 11:42AM  Novo Nordisk Pops On Successful Diabetes Drug Trial at Investor's Business Daily
08:45AM  Actavis Receives Final Approval for Generic Version of Subutex® PR Newswire
Feb-19-15 04:13PM  Nasdaq Climbs Modestly As Indexes Close Mixed at Investor's Business Daily
02:54PM  10 Most Popular Healthcare Stocks Among Hedge Funds at Insider Monkey
02:27PM  10 stocks billionaires love (hint: merger plays and credit cards) at MarketWatch
11:43AM  50 Stocks That Matter Most To Hedge Funds at Insider Monkey
10:57AM  Allergan Still Looks Like a Trophy Worth Winning for Actavis at The Wall Street Journal
10:40AM  Actavis (ACT) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
09:48AM  Actavis (ACT) Stock Higher Today as Analysts Increase Price Targets at TheStreet
09:18AM  [$$] Actavis to Sell $8.4 Billion in Shares to Fund Allergan Acquisition at The Wall Street Journal
08:23AM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:23AM  Actavis' Growth 'Underappreciated,' Sterne Agee Says Benzinga
07:38AM  Actavis Announces Proposed Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan PR Newswire
12:59AM  Billionaires Are Crazy About These 10 Stocks: Apple Inc. (AAPL), eBay Inc (EBAY), Alibaba Group Holding Ltd (BABA), More at Insider Monkey
Feb-18-15 06:45PM  Actavis Barred from Selling Generic Pulmicort Respules - Analyst Blog Zacks
05:34PM  Actavis Tops Views, Announces Name Change To Allergan at Investor's Business Daily
04:49PM  Pharmaceutical giant Actavis plans to rename itself Allergan at Los Angeles Times
03:36PM  Actavis Still Eyes Couple Billion Dollar' Deals After Allergan Bloomberg
03:36PM  Actavis Still Eyes Couple Billion Dollar Deals After Allergan at Bloomberg
03:18PM  10 Most Popular Stocks Among Hedge Funds at Insider Monkey
01:20PM  Teva to Commercialize Eagle's Cancer Drug in the U.S. - Analyst Blog Zacks
11:52AM  Actavis CEO expects further pharmaceutical industry consolidation Reuters
11:31AM  Actavis CEO says no "transformational" deals for now Reuters
11:09AM  Actavis plans name change to Allergan AP
09:59AM  Actavis Beats on Top and Bottom Lines, Will Change Name to Allergan at TheStreet
09:57AM  Housing Starts Down Sharply in January at MarketWatch
09:54AM  Wed., Feb. 18: Watch Berkshire Hathaway Stock at MarketWatch
09:20AM  Actavis Beats on Q4 Earnings, Allergan Acquisition on Track - Analyst Blog Zacks
09:11AM  Actavis beats profit estimates, raises forecast Reuters
09:07AM  Morning Movers: Fossil Tumbles on Earnings, Forecast; Jack in the Box Jumps on Qboba Sales at
08:46AM  What to expect from Actavis-Allergan merger: CEO at CNBC
08:06AM  Actavis (ACT) Beats on Q4 Earnings & Revenues - Tale of the Tape Zacks
07:50AM  Early movers: HLT, HOT, ACT, FOSL, CAT & more at CNBC
07:48AM  Actavis Changing Name to Allergan at The Wall Street Journal
07:42AM  Actavis to take Allergan name CNBC
07:15AM  ACTAVIS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:07AM  Q4 2014 Actavis PLC Earnings Release - Before Market Open CCBN
07:00AM  Actavis Announces Intention to Adopt "Allergan" Corporate Name PR Newswire
06:54AM  Actavis reports 4Q loss AP
06:49AM  Actavis adjusted profit beats estimates Reuters
06:45AM  Actavis Outlines Standalone Pharmaceutical Pipeline at Investor Meeting PR Newswire
06:30AM  Actavis Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91; Increases 2015 Standalone Forecast PR Newswire
05:42AM  Wall Street set to build on record high; Greece deal eyed at CNBC
Feb-17-15 05:13PM  Actavis Confirms Temporary Injunction From Appeals Court Related to Generic Pulmicort RESPULES® PR Newswire
04:00PM  Can Actavis (ACT) Keep the Earnings Streak Alive in Q4? - Analyst Blog Zacks
02:45PM  What to Watch in the Day Ahead - Wednesday, Feb. 18 Reuters
01:34PM  Stocks Turn Positive; Apple Marks New High at Investor's Business Daily
11:38AM  Buy More Stocks in a Top Sector at Forbes
08:36AM  Is a Surprise Coming for Actavis (ACT) This Earnings Season? - Tale of the Tape Zacks
Feb-16-15 03:30PM  Will Agios (AGIO) Surprise Estimates This Earnings Season? - Analyst Blog Zacks
03:20PM  Actavis to Divest Pharmatech to TPG, Brace up Supply Chain - Analyst Blog Zacks
01:00PM  Will NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog Zacks
12:30PM  Medtronic (MDT) Likely to Beat Q3 Earnings Estimates - Analyst Blog Zacks
12:00PM  Will DENTSPLY International (XRAY) Miss Earnings in Q4? - Analyst Blog Zacks
Feb-14-15 06:00AM  Jim Cramer's Top Stock Picks: ACT PCLN CLX HAIN WWAV NVAX at TheStreet
Feb-13-15 06:08PM  Salix, Top Drug Stocks Rally As Merger Mania Heats Up at Investor's Business Daily
06:00PM  Cramer's game plan for next week CNBC
04:28PM  Actavis Launches Generic Pulmicort RESPULES® PR Newswire
11:14AM  Ackman vs. Icahn: How Two Billionaires, Former Adversaries, Stack Up at TheStreet
10:30AM  Will Masimo Corp (MASI) Disappoint Q4 Earnings Estimates? - Analyst Blog Zacks
10:06AM  Can Radius Health (RDUS) Surprise This Earnings Season? - Analyst Blog Zacks
09:22AM  Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog Zacks
08:30AM  Actavis to Divest Pharmatech to TPG PR Newswire
Feb-12-15 07:00AM  Allergan CEO: How to survive an activist attack at Fortune
Feb-11-15 12:59PM  Apple Inc. (AAPL), Visa Inc (V), Actavis plc (ACT): Laurion Capital Reveals Top Stock Picks at Insider Monkey
10:40AM  Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog Zacks
08:02AM  Top Performing Large Cap Funds Makes Some Headway at Investor's Business Daily
Feb-10-15 04:44PM  ACTAVIS PLC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
03:41PM  Actavis to Divest U.S. Rights of Doryx to Mayne Pharma - Analyst Blog Zacks
03:30PM  DaVita Healthcare (DVA): What's in Store for Q4 Earnings? - Analyst Blog Zacks
02:40PM  Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog Zacks
01:18PM  EU mergers and takeovers (Feb 10) Reuters
10:40AM  Will Hospira (HSP) Miss Q4 Earnings on Low Precedex Sales? - Analyst Blog Zacks
09:31AM  Moody's: Large healthcare acquirers will show different rates of deleveraging in 2015 at Moody's
08:03AM  Allergan CEO: Fighting Ackman 'all consuming' CNBC
Feb-09-15 05:23PM  Actavis to Divest Doryx® to Mayne Pharma PR Newswire
03:20PM  Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog Zacks
03:07PM  Can Health Net (HNT) Beat Earnings Estimates This Season? - Analyst Blog Zacks
02:57PM  When Stock Breakouts Don't Act Like Breakouts at Investor's Business Daily
02:50PM  Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog Zacks
Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians' offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.